Nothing Special   »   [go: up one dir, main page]

ES8606295A1 - Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas. - Google Patents

Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.

Info

Publication number
ES8606295A1
ES8606295A1 ES541450A ES541450A ES8606295A1 ES 8606295 A1 ES8606295 A1 ES 8606295A1 ES 541450 A ES541450 A ES 541450A ES 541450 A ES541450 A ES 541450A ES 8606295 A1 ES8606295 A1 ES 8606295A1
Authority
ES
Spain
Prior art keywords
heteroazolidindionas
procedure
preparation
new
spire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES541450A
Other languages
English (en)
Other versions
ES541450A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of ES8606295A1 publication Critical patent/ES8606295A1/es
Publication of ES541450A0 publication Critical patent/ES541450A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE NUEVAS ESPIRO-E-HETEROAZOLIDINDIONAS. CONSISTE EN HIDROLIZAR A UN COMPUESTO DE FORMULA (II) CON UN ACIDO MINERAL COMO TOLUENSULFONICO, CLORHIDRICO, BROMHIDRICO, EN TOLUENO O 3-METIL-2-BUTANOL, ENTRE 80J Y 150JC, PARA OBTENER NUEVAS ESPIRO-3-HETEROAZOLIDINDIONAS DE FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. SIENDO: X H O ALQUILO C 1 A 4; Y Y Z, H, HAL, NITRO, TRIFLUORMETILO Y OTROS; O O S Y OTROS Y N 0 O 1. SE UTILIZAN COMO INHIBIDORES DE LA ENZIMA ALDOSA REDUCTORA EN EL TRATAMIENTO DE LAS COMPLICACIONES CRONICAS DE LA DIABETES COMO CATARATAS DIABETICAS, RETINOPATIA Y NEUROPATIA.
ES541450A 1984-03-23 1985-03-21 Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas. Expired ES8606295A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59301284A 1984-03-23 1984-03-23

Publications (2)

Publication Number Publication Date
ES8606295A1 true ES8606295A1 (es) 1986-04-16
ES541450A0 ES541450A0 (es) 1986-04-16

Family

ID=24372993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES541450A Expired ES8606295A1 (es) 1984-03-23 1985-03-21 Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.

Country Status (15)

Country Link
EP (1) EP0159143B1 (es)
JP (1) JPS60209572A (es)
KR (1) KR850006188A (es)
AU (1) AU563668B2 (es)
CA (1) CA1244443A (es)
DE (1) DE3561198D1 (es)
DK (1) DK131885A (es)
ES (1) ES8606295A1 (es)
FI (1) FI851170L (es)
GR (1) GR850704B (es)
HU (1) HU195783B (es)
IL (1) IL74667A (es)
PH (1) PH23921A (es)
PL (1) PL145198B1 (es)
PT (1) PT80145B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
AU2004222328B2 (en) 2003-03-14 2009-10-08 Merck Sharp & Dohme Corp. Aryl spirohydantoin CGRP receptor antagonists
WO2006031676A2 (en) * 2004-09-13 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirohydantoin cgrp receptor antagonists
DE602006019304D1 (de) 2005-11-18 2011-02-10 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
CN111732545B (zh) * 2020-06-08 2023-03-10 华侨大学 一种2,3-二氢螺[咪唑-4,1′-茚]类化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
ES8400116A1 (es) * 1981-10-13 1983-10-16 Pfizer "un procedimiento por analogia para la preparacion de derivados de espiro-oxindol-oxazolidindiona".
ZA832679B (en) * 1982-05-07 1983-12-28 Ici Plc Indoline derivatives
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications

Also Published As

Publication number Publication date
IL74667A (en) 1988-12-30
AU563668B2 (en) 1987-07-16
DK131885D0 (da) 1985-03-22
FI851170A7 (fi) 1985-09-24
FI851170A0 (fi) 1985-03-22
AU4025185A (en) 1985-09-26
EP0159143B1 (en) 1987-12-16
PL145198B1 (en) 1988-08-31
FI851170L (fi) 1985-09-24
PT80145A (en) 1985-04-01
PH23921A (en) 1990-01-23
DE3561198D1 (en) 1988-01-28
CA1244443A (en) 1988-11-08
IL74667A0 (en) 1985-06-30
EP0159143A1 (en) 1985-10-23
KR850006188A (ko) 1985-10-02
PT80145B (en) 1987-03-23
DK131885A (da) 1985-09-24
GR850704B (es) 1985-07-19
HUT37603A (en) 1986-01-23
JPS60209572A (ja) 1985-10-22
PL252487A1 (en) 1985-10-08
HU195783B (en) 1988-07-28
ES541450A0 (es) 1986-04-16

Similar Documents

Publication Publication Date Title
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
KR830006174A (ko) 기관지 항경련성 화합물 제조방법
KR870006016A (ko) N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법
MX9307779A (es) Compuestos benzoicos fundidos.
PT83647B (pt) Processo para a preparacao de novos derivados de benzimidazole com actividade farmacologica e de composicoes farmaceuticas que os contem
ES8606336A1 (es) Un procedimiento para la preparacion de derivados de tiazol 2,4-disustituidos
PT674634E (pt) Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
GB2025413B (en) 4,5 13-prostatrienoic acid derivatives
ES2036562T3 (es) Un procedimiento para produccion de un derivado de pirrolidinamida.
KR910000730A (ko) N-헤테로아릴-푸린-6-아민, 이의 제조방법 및 약제로서의 이의 용도
KR920006327A (ko) 벤즈이미다졸 유도체, 이의 제조방법 및 용도
ES8606295A1 (es) Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.
PT80820B (pt) Processo para a preparacao de derivados de 1,3-propilidenodifosfonato 2-substituidos
ATE165827T1 (de) Herstellung von n-acetylneuraminsäure-derivaten
ES2053856T3 (es) Derivados del acido 4-quinoleino carboxilico utiles para el tratamiento de enfermedades de la piel y del muco-epitelio.
JPS5649361A (en) Carbostyril derivative
DE3667470D1 (de) Griseolinsaeurederivate, ihre herstellung und ihre verwendung.
PT84564B (pt) Processo para a preparacao de derivados de acidos dicarboxilicos diazotados substituidos com actividade nootropica
DK102892D0 (da) Purin-derivater, farmaceutisk praeparat omfattende forbindelserne samt forbindelser til brug som mellemprodukter
ES8503676A1 (es) Procedimiento de producir derivados de acido oxazolacetico
ES2068942T3 (es) Derivados del acido butenoico.
ATE27813T1 (de) N-substituierte 1-(4'-alkylsulfonylphenyl)-2amino-1,3-propanediol-derivate.
ES543407A0 (es) Un metodo para producir acido dihidrodesoxigriseolico y sa- les y esteres del mismo
ES8706821A1 (es) Metodo de estabilizar un precursor de uroquinasa
MX169465B (es) Procedimiento para la obtencion de derivados del acido pirimidilfosforico y productos intermedios